<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130205</url>
  </required_header>
  <id_info>
    <org_study_id>Uppsala University Hospital</org_study_id>
    <nct_id>NCT03130205</nct_id>
  </id_info>
  <brief_title>Biomarker Study in Pancreatic Neuroendocrine Tumours</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The biology of pancreatic neuroendocrine tumors can change during the disease course. This
      evolution of disease can manifest through increases in tumor proliferation rate, resistance
      to medical therapy and/or a change in tumor hormone secretion. This study aims to
      characterize how the biology of pancreatic neuroendocrine tumors change over time, measured
      by; patient symptoms, biochemistry, contrast enhanced computed tomography, FDG-PET and core
      needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation).
      Uptake on 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction
      of patients with spatial heterogeneity in FDG uptake as well as metachronous changes in all
      collected data will be documented. Biomaterial from whole blood and core needle biopsies will
      be characterized on the molecular level, and those findings will be integrated to the above
      specified clinical parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between FDG-PET and tumor biology</measure>
    <time_frame>Through study completion, an average of 3 years.</time_frame>
    <description>18F-FDG-PET SUVmax correlation to Ki67 index (determined as percentage of tumor cells with positive Ki67 imunohistochemical staining).</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Core Needle Biopsy</intervention_name>
    <description>Core Needle Biopsy is performed from liver metastasis.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Computed Tomography</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FDG-PET</intervention_name>
    <description>18F Fluorodeoxyglucose Positron emission tomography</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>3 EDTA tubes drawn from peripheral vein</description>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Molecular genetic analysis</intervention_name>
    <description>Performed on biomaterial from peripheral vein and core needle biopsy</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Core needle Biopsy Phlebotomy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-resectable metastatic pancreatic neuroendocrine tumors at the Department
        of Endocrine Oncology, Uppsala, Sweden.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Informed consent

          -  WHO performance status ≤2

          -  Progressive disease (as defined by the local investigator) or newly diagnosed disease
             (defined as prior to medical or oncological intervention except for somatostatin
             analogue treatment).

          -  Pathology confirmed diagnosis of pancreatic or duodenal neuroendocrine tumour WHO
             G1-G3.

             o Exception: In newly diagnosed patients with high suspicion of PNET based on clinical
             and radiological parameters where tissue sample have not yet been obtained. These
             patients may be included and subsequently excluded if pathology cannot confirm NET.

          -  Biopsy procedure not associated with inappropriate risk as determined by the
             responsible physician.

        Exclusion Criteria:

          -  Patient does not consent

          -  Permanent risk factors for biopsy

               -  Long term treatment with anticoagulant that cannot be temporarily paused without
                  unacceptable risk.

               -  Permanent coagulation disorder

          -  Pregnancy or no contraceptive in fertile women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbro Eriksson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademiska Sjukhuset, Uppsala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbro Eriksson, MD PhD</last_name>
    <phone>+46186110000</phone>
    <email>barbro.eriksson@medsci.uu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joakim Crona, MD PhD</last_name>
    <phone>+46186118630</phone>
    <email>joakim.crona@medsci.uu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbro Eriksson, MD PhD</last_name>
      <phone>+46186110000</phone>
      <email>barbro.eriksson@medsci.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Joakim Crona, MD PhD</last_name>
      <phone>+46186118630</phone>
      <email>joakim.crona@medsci.uu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Barbro Eriksson</investigator_full_name>
    <investigator_title>Professor, Senior Attending</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

